Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
AdipoUpX™ Human IL6 Lentiviral Particle (Overexpression)
Cat. No.:
V1225XX419
Species:
Human
Target Gene:
IL6
Vector System:
Lentiviral
Modulation Type:
Overexpression
SPECIFIC INQUIRY
Add to basket
Product Overview
Description:
AdipoUpX™ Human IL6 Lentiviral Particle (Overexpression) is a high-titer system for the specific and stable expression of the human IL6 gene. Its stable overexpression enables researchers to explore the dual roles of IL6 in metabolic inflammation and fatty acid oxidation. The lentivirus characteristic of genome integration establishes reliable cell models for long-term signaling investigation. Our vector system offers high flexibility for customization, and comprehensive quality control is performed on all particles to ensure safety and experimental reliability.
Production Cell Line:
HEK293T
Promoter:
Ubi; CMV; EF1a; Others
Product Availability:
Produced Upon Order
Specification
Titer Test:
qPCR
Insert Verification:
PCR analysis was performed to verify the complete genomic sequence of all viral vector preparations.
Sterility Test:
This product was certified sterile following successful microbial growth analysis.
Mycoplasma Test:
The production quality control confirmed the absence of any mycoplasmal agents.
Other QC:
This comprehensive process includes customized supplementary testing alongside in vitro and in vivo transduction assessments to elucidate transgene expression and functionality.
Storage:
To maintain product integrity, immediate transfer of the vector to a -80 °C is essential following its receipt.
Stability:
Continuous storage at -80°C ensures excellent long-term stability for 6-12 months. Once thawed, the product's working solution should be refrigerated at 4°C and used within 2-3 weeks.
Shipping Condition:
Our lentivirus viral products are shipped using dry ice.
Handling Notes:
Ensure all operations are performed within a biosafety cabinet; upon receiving the vector, immediately aliquot it into low-protein-binding tubes and store according to specified conditions, thus avoiding the titer loss caused by sensitivity to temperature fluctuations and freeze-thaw cycles.
Intended Use:
This product is intended for research use only and is not for use in diagnosis or therapeutic applications.
Product Disclaimer:
Given the diversity and complexity of experimental conditions, we do not guarantee product performance or experimental results in any specific application, despite our company's commitment to product quality and the rigorous internal QC inspections all products have undergone. Ultimate responsibility remains with the user for all operational processes, including storage, handling, and compliance with safety and biosafety protocols.
Target Profile
Gene Name:
IL6
Full Name:
Interleukin 6
Gene Symbol:
CDF; HGF; HSF; BSF2; IL-6; BSF-2; IFNB2; IFN-beta-2
Gene ID:
3569
RefSeq ID-1:
NP_000591.1
RefSeq ID-2:
NM_000600.5
Summary:
IL6 encodes a powerful cytokine that operates as an endogenous pyrogen and is a key mediator of the acute and chronic inflammatory response. Produced primarily at sites of inflammation, it is secreted into the serum and triggers a systemic transcriptional inflammatory response via the IL6 receptor (IL6R$\alpha$). IL6 is critical for the maturation of B cells and the induction of fever. Its dysregulation is implicated in a wide range of inflammation-associated diseases, including susceptibility to diabetes mellitus, systemic juvenile rheumatoid arthritis, and severe outcomes in viral infections like COVID-19 (due to SARS-CoV-2).